Company Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2026 am IST			5-day change	1st Jan Change
17.55 ^USD	-6.05%		-12.05%	-18.45%

15/05	Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says	MT
14/05	Regenxbio shares sink as safety concerns overshadow muscle disorder therapy trial win	RE

Business description: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Number of employees: 835

Sales by Activity: Sarepta Therapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Discovering, Developing, Manufacturing and Delivering Therapies	70Cr	93Cr	124.33Cr	190.2Cr	219.82Cr

See all business segments

Geographical breakdown of sales: Sarepta Therapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	70Cr	93Cr	124.33Cr	190.2Cr	219.82Cr

See all geographic segments

Executive Committee: Sarepta Therapeutics, Inc.

Manager	Title	Age	Since
Douglas Ingram CEO	Chief Executive Officer	63	26/06/2017
Ryan Wong DFI	Director of Finance/CFO	47	16/07/2025
Ian Estepan DFI	Director of Finance/CFO	50	14/12/2020
James Richardson CTO	Chief Tech/Sci/R&D Officer	-	01/02/2025
Rachael Potter CTO	Chief Tech/Sci/R&D Officer	-	-

See SAREPTA THERAPEUTICS, INC. governance

Composition of the Board of Directors: Sarepta Therapeutics, Inc.

Director	Title	Age	Since
M. Wilsey CHM	Chairman	73	16/04/2015
Hans Lennart Rudolf Wigzell BRD	Director/Board Member	87	01/06/2010
Richard Barry BRD	Director/Board Member	67	02/06/2015
Claude Nicaise BRD	Director/Board Member	73	02/06/2015
Stephen Mayo BRD	Director/Board Member	64	16/11/2021
Michael Chambers BRD	Director/Board Member	51	02/06/2022
Kathryn Boor BRD	Director/Board Member	67	02/06/2022
Deirdre Connelly BRD	Director/Board Member	65	12/09/2024

Composition of the Board of Directors

Shareholders: Sarepta Therapeutics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 13.08 %	1,37,33,435	13.08 %	287 M $
AQR Capital Management LLC 7.72 %	81,04,869	7.72 %	169 M $
Vanguard Portfolio Management LLC 6.43 %	67,51,168	6.43 %	141 M $
Vanguard Portfolio Management LLC 6.325 %	66,40,692	6.325 %	139 M $
STATE STREET CORPORATION 6.299 %	66,13,314	6.299 %	138 M $

List of SAREPTA THERAPEUTICS, INC. shareholders

Company details: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

215 First Street

02142, Cambridge

+617 274 4000

http://www.sarepta.com

address Sarepta Therapeutics, Inc.(SRPT)

Diagnostic & Testing Substances Manufacturers

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SAREPTA THERAPEUTICS, INC.	-6.05%	-12.05%	-51.83%	-88.20%	185.29Cr
ULTRAGENYX PHARMACEUTICAL INC.	-3.10%	-4.29%	-29.80%	-49.14%	245.47Cr
BIONOTE, INC.	-3.40%	-0.20%	+7.34%	-7.53%	34Cr
DK LIFE SCIENCE CO., LTD.	-0.96%	-6.06%	-32.46%	-	6.62Cr
Average	-3.38%	-4.84%	-26.69%	-48.29%	117.74Cr
Weighted average by Cap.	-4.25%	-6.98%	-35.85%	-61.71%